Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
West Palm Beach, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Atlanta, GA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Woodstock, GA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Woodstock, GA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Boise, ID
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Boise, ID
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Meridian, ID
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Apex Medical Research, MI, Inc
mi
from
Chicago, IL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Apex Medical Research, MI, Inc
mi
from
Chicago, IL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Chicago, IL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Avon, IN
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Avon, IN
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Greenfield, IN
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Greenfield, IN
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Muncie, IN
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Muncie, IN
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Council Bluffs, IA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Topeka, KA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Topeka, KA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Owensboro, KY
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Owensboro, KY
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Oxon Hill, MD
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Oxon Hill, MD
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Fall River, MA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Fall River, MA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
St. Louis, MO
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Washington, MO
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Washington, MO
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Omaha, NE
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Nashua, NH
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Nashua, NH
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Elizabeth, NJ
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Elizabeth, NJ
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Haddon Heights, NJ
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Haddon Heights, NJ
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Rosedale, NY
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Rosedale, NY
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Calabash, NC
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Calabash, NC
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Charlotte, NC
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Greensboro, NC
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Morganton, NC
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Morganton, NC
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Winston-Salem, NC
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Dayton, OH
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Maumee, OH
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Maumee, OH
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Norman, OK
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Norman, OK
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Oklahoma City, OK
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Feasterville, PA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Feasterville, PA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Harleysville, PA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Harleysville, PA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Levittown, PA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Levittown, PA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Uniontown, PA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Uniontown, PA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Fort Mill, SC
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Fort Mill, SC
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Greer, SC
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Spartanburg, SC
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Spartanburg, SC
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Crossville, TN
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Crossville, TN
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Knoxville, TN
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Carrollton, TX
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Carrollton, TX
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Dallas, TX
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Fort Worth, TX
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Houston, TX
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Irving, TX
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Irving, TX
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Lewisville, TX
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Lewisville, TX
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
McKinney, TX
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
McKinney, TX
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
New Braunfels, TX
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
New Braunfels, TX
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Plano, TX
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
San Antonio, TX
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials